TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03313076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (fish oil)
Description: 4 capsules comprising approximately 2 grams of Eicosapentaenoic acid/Docosahexaenoic acid (EPA/DHA) in a 3:2 ratio (this will require a total dose of 4 grams of fish oil). This will be administered daily, by mouth for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (fish oil)
Description: 4 capsules comprising approximately 2 grams of Eicosapentaenoic acid/Docosahexaenoic acid (EPA/DHA) in a 3:2 ratio (this will require a total dose of 4 grams of fish oil). This will be administered daily, by mouth for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol)
Description: 1 capsule containing 2000 IU of Vitamin D3. This will be administered daily, by mouth for 6 weeks following enrollment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol)
Description: 1 capsule containing 2000 IU of Vitamin D3. This will be administered daily, by mouth for 6 weeks following enrollment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3 (cholecalciferol) placebo
Description: 1 capsule containing inert substance. This will be administered daily, by mouth for 6 weeks following enrollment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol) placebo
Description: 1 capsule containing inert substance. This will be administered daily, by mouth for 6 weeks following enrollment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid placebo
Description: 4g of corn/soy oil blend in 4 softgels. This will be administered daily, by mouth for 6 weeks following enrollment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omega-3 fatty acid placebo
Description: 4g of corn/soy oil blend in 4 softgels. This will be administered daily, by mouth for 6 weeks following enrollment.
Study: NCT02550886

Intervention type: OTHER
Intervention: Survey
Description: Patients and their caregivers will be asked to complete surveys about their expected and actual time taken off from work. They will also answer questions about the patient's recovery, as well as the patient/caregiver relationship.
Study: NCT02192827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Sodium Phosphate Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Sodium Phosphate Injection
Study: NCT02335827

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: irreversible electroporation
Description: Percutaneous (CT-guided and/or US-guided) or open IRE with voltage in level B for renal tumors

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: irreversible electroporation
Description: Percutaneous (CT-guided and/or US-guided) or open IRE with voltage in level B for renal tumors

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: irreversible electroporation
Description: Percutaneous (CT-guided and/or US-guided) or open IRE with voltage in level B for renal tumors
Study: NCT02261727

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Theophylline
Description: Theophylline is an oral methylxanthine which relaxes smooth muscle through its action as a phosphodiesterase inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Theophylline
Description: Theophylline is an oral methylxanthine which relaxes smooth muscle through its action as a phosphodiesterase inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone is an oral glucocorticosteroid which has anti-inflammatory properties

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for prednisone)
Description: * Arm 1 : Theophylline Placebo 1 tab twice daily and Prednisone placebo 1 tab once daily~* Arm 2 : Theophylline 100mg 1 tab twice daily and Prednisone placebo 1 tab once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for prednisone)
Description: * Arm 1 : Theophylline Placebo 1 tab twice daily and Prednisone placebo 1 tab once daily~* Arm 2 : Theophylline 100mg 1 tab twice daily and Prednisone placebo 1 tab once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Theophylline)
Description: One tablet twice daily in arm 1 (theophylline placebo 1 BD + prednisone placebo 1 once daily)
Study: NCT02329769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO044 SC 6 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO044 IV 6 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO044 IV 9 mg/kg
Study: NCT05506189

Intervention type: OTHER
Intervention: mobile application program with human coach
Description: 6-months mobile application program with human coach for life-style modifiation including diet and exercise
Study: NCT03269123

Intervention type: DEVICE
Group type: OTHER
Intervention: Pressop 1
Description: A pressure device attached to the spectacles which mimics a sensory trick (geste Antagoniste)
Study: NCT03923569

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Overnight polysomnography
Description: Overnight polysomnography with evaluation of each form of epileptiform activity during each vigilance state and memory scores at the overnight retention test

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Overnight polysomnography
Description: Overnight polysomnography with evaluation of each form of epileptiform activity during each vigilance state and memory scores at the overnight retention test

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: blood sample
Description: blood sample for genetic testing of the Apolipoprotein E

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: high-resolution MRI scan
Description: Evaluation of anomalies in brain structure and functional resting state connectivity

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: high-resolution MRI scan
Description: Evaluation of anomalies in brain structure and functional resting state connectivity

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: neuropsychological evaluation
Description: neuropsychological evaluation including episodic memory tests before an overnight polysomnography

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: neuropsychological evaluation
Description: neuropsychological evaluation including episodic memory tests before an overnight polysomnography
Study: NCT02636088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study: NCT03267121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate Tablets
Description: 500 mg qd.p.o. every day for 21 days as a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur Gimeracil Oteracil Potassium Capsules
Description: 25mg/㎡ bid p.o. every day for 14 days as a cycle
Study: NCT04778254

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEK attachment retained obturator
Description: attachment retained obturator for management of hemi maxillectomy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: metalic attachment retained obturator
Description: attachment retained obturator for management of hemi maxillectomy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional obturator
Description: clasp retained obturator for management of hemi maxillectomy
Study: NCT01018498

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Restricted FODMAPs diet
Description: Restricted fermentable substrate diet
Study: NCT01453855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost ophthalmic solution, 0.003%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost ophthalmic solution, 0.004%
Study: NCT02567890

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based DBI
Description: Participants will go through a four week interactive program that will improve body acceptance. Includes some homework assignments and monitoring.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Expressive writing
Description: Participants will be asked to reflect upon issues related to body image.
Study: NCT03699007

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graded Exposure Therapy (GET Living)
Description: The protocol consists of 12 interdisciplinary sessions, 1-hour each, delivered twice a week, for an average of 6 weeks. Phase I-III are conducted with the psychologist, physical therapist, adolescent, and parent (as developmentally appropriate). Patient and parent will complete daily diaries and patients will wear the Actigraph throughout the duration of treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multidisciplinary Pain Management (MPM)
Description: The protocol consists of 12 multidisciplinary sessions, 1-hour each, delivered twice a week, for an average of 6 weeks. Sessions will alternate between psychological CBT sessions and Physical Therapy sessions. Patient and parent will complete daily diaries and patients will wear the Actigraph throughout the duration of treatment. The parent will also participate in 3 additional parent-only sessions with the psychologist to address parental coping skills.
Study: NCT01751308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel (XRP6258)
Description: Pharmaceutical form: Injection Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel (XRP6258)
Description: Pharmaceutical form: Injection Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel (XRP6258)
Description: Pharmaceutical form: Injection Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel (XRP6258)
Description: Pharmaceutical form: Injection Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel (XRP6258)
Description: Pharmaceutical form: Injection Route of administration: Intravenous
Study: NCT02127437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide
Description: 120 mg, subcutaneously, once every 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: 0,5 ml, subcutaneously, once every 4 weeks
Study: NCT03046875

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous Spinal Cord Stimulation
Description: Transcutaneous Spinal Cord Stimulation is a non-invasive mechanism to enhance excitation of spinal neural circuitry and represents a promising supplement to existing physical therapy programs. Transcutaneous Spinal Cord Stimulation will be applied (via the Vectra Neo) using a 5cm x10cm oval electrode placed midline on the skin between spinous process T11 -T12 as a cathode and two 7.5cm x 13cm rectangular electrodes placed symmetrically on the skin over the lower abdomen as anodes.7,9 A symmetrical biphasic rectangular waveform, at 50Hz and 1millisecond, will be used to provide 30 continuous minutes of stimulation.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Sham procedures, well documented in Transcranial DC Stimulation (tDCS), will be used. Electrodes will be placed as they are in the Transcutaneous Spinal Cord Stimulation condition. Stimulation will be applied at subject's maximum intensity for 30 seconds and then discontinued.
Study: NCT03001674

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conductance catheterization
Description: CD Leycom Conductance Catheter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conductance catheterization
Description: CD Leycom Conductance Catheter
Study: NCT01554137

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: isokinetic strength training
Description: The experimental group will follow a program of 18 sessions (3 sessions per week for 6 weeks) with a physiotherapy treatment (30 minutes) and occupational therapy (30 minutes), and a building session isokinetic concentric mode extensor and flexor muscles of the elbow extensors and wrist flexors.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: passive motion
Description: The control group will follow a program of 18 sessions of physiotherapy and occupational therapy combined with 18 sessions of passive motion in flexion-elbow extension, wrist flexion-extension on the isokinetic device
Study: NCT01263639

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orthopaedic Attending Biosketch Card
Description: The intervention group will receive an attending photo/biosketch card within 24 hours of admission while the control group will not. The biosketch card will include a picture of the attending orthopaedic surgeon with a brief synopsis of his or her: education background, specialty, surgical interests, research interests, and other interests including hobbies.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care - No biosketch card
Description: Standard of care
Study: NCT02981875

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oculomotor training
Description: a sequence of vision training exercises which focused mainly in oculomotor skill

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo vision training exercises involving minimal accommodation and vergence eye movement.
Study: NCT00252057

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Re-Engineered Hospital Discharge
Description: The Re-engineered Hospital Discharge (Project RED) intervention provides a set of 11 discrete, mutually reinforcing components provided by a Discharge Advocate and re-enforced by a telephone call after discharge by a clinical pharmacist.
Study: NCT04646759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant combined with Pyrotinib
Description: Fulvestrant 500mg was injected intramuscularly on D1, D15, D28 and D28 Pyrotinib 400mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine combined with Pyrotinib
Description: Capecitabine 1000mg/m\^2 bid d1-d14，every 21 days Pyrotinib 400mg daily
Study: NCT03129659

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Coronary CT Angiography
Description: Coronary CT angiography
Study: NCT02010164

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Co-enzyme Q10
Description: 600mg for 3 months
Study: NCT03594188

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anesthetic methods
Description: Patients will receive standard GA or LA for RF surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: anesthetic methods
Description: Patients will receive standard GA or LA for RF surgery.
Study: NCT03668483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: A 6-min walk test, peripheral and respiratory muscle strength measurements, and a dyspnea rating scale Mmrc will be applied to the lung transplantation candidates who are trained in 3-month hospital-based preoperative exercise training in the Pulmonary Rehabilitation unit. The tests will be carried out at the beginning and end of rehabilitation.
Study: NCT05477290

Intervention type: PROCEDURE
Intervention: Trigger Finger Release through Transverse Incision
Description: At the level of the A1 pulley, a transverse incision will be made and the flexor pulley will be exposed with blunt dissection. The pulley will be transected and the wound will subsequently be closed with 4.0 Monocryl after ensuring complete release.

Intervention type: PROCEDURE
Intervention: Trigger Finger Release through Oblique Incision
Description: At the level of the A1 pulley, a oblique incision will be made and the flexor pulley will be exposed with blunt dissection. The pulley will be transected and the wound will subsequently be closed with 4.0 Monocryl after ensuring complete release.

Intervention type: PROCEDURE
Intervention: Trigger Finger Release through Vertical Incision
Description: At the level of the A1 pulley, a vertical incision will be made and the flexor pulley will be exposed with blunt dissection. The pulley will be transected and the wound will subsequently be closed with 4.0 Monocryl after ensuring complete release.
Study: NCT00832507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cicletanine
Description: Cicletanine capsules 150 mg or 300 mg administered orally once or twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cicletanine
Description: Cicletanine capsules 150 mg or 300 mg administered orally once or twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cicletanine
Description: Cicletanine capsules 150 mg or 300 mg administered orally once or twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cicletanine
Description: Cicletanine capsules 150 mg or 300 mg administered orally once or twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cicletanine Placebo
Description: Placebo to match cicletanine administered orally once daily, followed by active cicletanine in the blinded extension period
Study: NCT04971304

Intervention type: DRUG
Intervention: Receipt of granulocyte-colony stimulating factor
Description: Receipt of originator or biosimilar

Intervention type: DRUG
Intervention: Receipt of granulocyte-colony stimulating factor
Description: Receipt of originator or biosimilar
Study: NCT03326843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag 60 mg
Description: Oral avatrombopag administered once daily for 5 days prior to procedure.
Study: NCT00657891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: 0.016 mg/kg/IgE(iU/ml)/4 wks, Subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Injection
Study: NCT00705783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole depot
Description: Aripiprazole depot was supplied in 400 mg lyophilized vials. Patients received aripiprazole 300 mg if they were unable to tolerate aripiprazole 400 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo depot
Description: Placebo depot was supplied in 400 mg lyophilized vials.
Study: NCT03783390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Youth randomized to the active condition will participate in an organized exercise program. During the exercise program, adolescents will participate in a supervised structured exercise (treadmill walking/cycling on stationary bike) on 3 days equivalent to approximately 180 min/week of moderate-intensity exercise. The rationale for this dose of structured exercise is based on national (ADA) and international physical activity recommendations for youth of 60 minutes/day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Newsletter
Description: Families will receive a monthly newsletter with parenting tips, sample praise statements, and child-appropriate activities and recipes identical to what has been used in the work of leaders in the field of pediatric obesity. Previous research suggests that newsletter/mail interventions are well received by participants and are frequently included in federally funded health intervention studies.
Study: NCT03127371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: Patients undergoing incision and drainage of abscess will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive Nitrous Oxide gas via a gas mixer device while undergoing standard incision and drainage of cutaneous abscess . The device will mix and deliver nitrous oxide and oxygen in a 1:1 ratio, at a fixed concentration of 50%/50%. The on demand valve requires patient inspiration to trigger dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Patients undergoing incision and drainage of abscess will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive 100% oxygen gas via the Nitrous Oxide gas mixer device while undergoing standard incision and drainage of cutaneous abscess . The device will deliver only oxygen at a fixed concentration of 100%. The on demand valve requires patient inspiration to trigger dosing.
Study: NCT02461992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous infusions of Xyntha
Description: A single dose 50IU/kg dose of Xyntha administered by intravenous infusion within 10 minutes on Day 1
Study: NCT00724997

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: GHB01L1
Description: Study medication administered as a single intranasal aerosol (520ul) at doses of 6.4 log10, 6.7 log10, 7.0 log10, 7.4 log10 and 7.7 log10 TCID50/volunteer

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: GHB01L1
Description: Study medication administered as a single intranasal aerosol (520ul) at doses of 6.4 log10, 6.7 log10, 7.0 log10, 7.4 log10 and 7.7 log10 TCID50/volunteer

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: GHB01L1
Description: Study medication administered as a single intranasal aerosol (520ul) at doses of 6.4 log10, 6.7 log10, 7.0 log10, 7.4 log10 and 7.7 log10 TCID50/volunteer

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: GHB01L1
Description: Study medication administered as a single intranasal aerosol (520ul) at doses of 6.4 log10, 6.7 log10, 7.0 log10, 7.4 log10 and 7.7 log10 TCID50/volunteer

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: GHB01L1
Description: Study medication administered as a single intranasal aerosol (520ul) at doses of 6.4 log10, 6.7 log10, 7.0 log10, 7.4 log10 and 7.7 log10 TCID50/volunteer
Study: NCT00362089

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Marinol D-40
Description: Marinol D-40, three capsules per day, from 15th week of gestation until 4th month of lactation
Study: NCT03988335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RIST4721
Description: RIST4721 oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral solution
Study: NCT00978029

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sublingual tablet, once daily

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCH 39641
Description: Allergy immunotherapy tablet (sublingual)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCH 39641
Description: Allergy immunotherapy tablet (sublingual)
Study: NCT00902785

Intervention type: OTHER
Intervention: no drug
Description: observational no drug
Study: NCT02933697

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Patients will be instructed to take one tablet of 2.5 mg twice daily: one tablet in the morning and one in the evening at approximately the same time every day (with about 12 hours gap) irrespective of the time of dialysis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenprocoumon
Description: Subjects in phenprocoumon treatment group will receive phenprocoumon individually adjusted to an INR of 2.0-3.0 as recommended in the appropriate SmPC for AF patients.